GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers.
GemVax AS, a subsidiary of Pharmexa A/S, is developing GV-1001, an injectable formulation of a promiscuous MHC class II peptide derived from the telomerase reverse transcriptase catalytic subunit (hTERT), for the potential treatment of solid tumors, including pancreatic, liver and NSCLC. GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer.
Nava-Parada
Pilar
P
The Johns Hopkins University and the Sidney Kimmel, Comprehensive Cancer Center Department of Oncology, Bunting Blaustein Cancer Research Building, Baltimore, MD 21231-1000, USA.
Emens
Leisha A
LA
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy*; D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D004353:Drug Evaluation, Preclinical; D006801:Humans; D007267:Injections; D010190:Pancreatic Neoplasms / Q000276:immunology / Q000628:therapy*; D019098:Telomerase / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology*; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
D019496:Cancer Vaccines; D022223:Vaccines, Subunit; D019098:Telomerase